Orientation 2009 **IBD** Overview Tad Dryden, MD MSPH **Associate Professor** University of Louisville






- Review the etiology of chronic inflammatory bowel disease
- Discuss diagnosis, differential diagnosis
- Review measures of disease activity
- Discuss IBD therapy

### **IBD-Background Information**

#### Inflammation

- gut's only response to myriad of potential insults
- Minority of new occurrences of IBD associated with straightforward effort of establishing positive diagnosis


   No gold standard test exists
  - Casual diagnosis of IBD has many ramifications
- Bottom line:
  - Diagnosing IBD continues to be a challenge!



### **Environmental Triggers of IBD**


#### Alter Flora

**Antibiotics** 



Diet

#### Psychosocial Factors and IBD: Possible Points of Impact



### **Components of IBD Diagnosis**

- Clinical picture
- Endoscopic information/pathologic specimens
- Radiographic evidence
- Chronic course of symptoms

### Constructing the Diagnosis of IBD


 Careful process of putting together pieces of a puzzle to accumulate enough evidence to diagnose IBD



### Age & Sex Incidence of IBD

Ulcerative Colitis

Crohn's Disease



### **Historical Points Suggestive of IBD**

- ↑ stool frequency, ↓ consistency most common presenting sx of UC and CD
  - Altered bowel habits need not be present in either
  - Proctitis, in particular, may present with constipation
- Abdominal pain second most common symptom

   RLQ pain exacerbated by eating: CD
   LLQ cramping before BM, relieved by BM: UC
   Tenesmus: proctitis, most likely UC, occ CD

### **Historical Points Suggestive of IBD**

- Alternating diarrhea and constipation more strongly suggest IBS vs IBD
- Nocturnal diarrhea more common in IBD
- Functional symptoms remaining after bout of enteric infection may be confusing
  - Lingering abdominal pain, loose/urgent stools should prompt objective evaluation by endo/path

### Physical Findings in IBD

- Crohn's Disease
  - Oral lesions
  - Ocular lesions
  - Skeletal manifestations
  - Skin lesions
    - Erythema nodosum
  - Abdominal exam
    - Mass
  - Perianal disease
    - Skin tags
    - Anal fissure
    - Perianal fistula
    - Anal stenosis

- Ulcerative colitis
  - Oral lesions
  - Ocular lesions
  - Skeletal manifestations
  - Skin lesions
    - Pyoderma
  - Abdominal exam
    - Tenderness
  - Perianal disease
    - Rectovaginal fistula

### **Oral Lesions**



### **Ocular Lesions**





### **Cutaneous Lesions**






#### Perineal Complications of Crohn's Disease



Common Peri-Anal Conditions Not to be confused with Crohn's

- Uncomplicated fistula-in-ano
   Does not traverse the internal anal sphincter
- Anal fissure (posterior mid-line)

### Systemic Complications of Ulcerative Colitis Peripheral Arthritis



- Monoarticular
- Asymmetrical
- Large > small joint
- No synovial destruction
- No subcutaneous nodules
  - Seronegative

#### Systemic Complications of Ulcerative Colitis Central (Axial) Arthritis



Ankylosing Spondylitis and Sacro-iliitis

#### Systemic Complications of Ulcerative Colitis Bile Duct Lesions



Sclerosing cholangitis

Cholangiocarcinoma

### **Historical Information-Summary**

Presenting signs and symptoms may suggest a particular diagnosis

 Often not definitive

• Usually requires further investigation!

### **Useful Laboratory Tests**

Blood work
 – CBC, TSH, ESR, c-RP





#### Stool studies

- Ova and parasites, stool culture, fecal WBC,
  - C. diff toxin A/B
- Fecal lactoferrin, calprotectin
- Serologic markers
  - ASCA, ANCA, anti-OmpC, anti-CBir1, anti-I2

### **Diagnostic Tools for IBD**

Endoscopy with pathology





### **Diagnostic Tools for IBD**

#### Barium studies (UGI/SBFT, ACBE)



### **Diagnostic Tools for IBD**

#### Capsule/wireless endoscopy







#### Capsule endoscopy

#### Not suitable for routine diagnosis


 best indication is for strong suspicion of Crohn's despite normal conventional testing (e.g., anemia, weight loss, elevated CRP/ESR, etc)

#### Complications

- capsule retention
  - in established Crohn's disease 5%
  - in suspected Crohn's disease before obstructive symptoms – less than 1%

# Small intestinal Crohn's disease as seen by wireless capsule endoscopy








### Capsule endoscopy in Crohn's disease

- Detects erosions in suspected Crohn's disease with negative SBFT / colonoscopy
- Need blinded comparison studies vs other imaging to calculate true sensitivity and specificity
- Need to determine specificity (prevalence of SB erosions in general population)
- Need to clarify safety in stricturing Crohn's disease – patency capsule may help

### **CT enterography**



#### **Peri-enteric fat stranding**




Adapted from Loftus, Oral presentation, ACG 2006

#### **Fistulas**




#### Tracts

- Usually enhancing (unless perianal)
- ± fluid / air
- Enterocutaneous



Adapted from Loftus, Oral presentation, ACG 2006

#### Inflammatory stricture with proximal bowel dilation



### MR enterography



#### **MR enterography**

No ionizing radiation

Comprehensive evaluation of bowel and perianal fistula

Functional evaluation (is narrowing due to stricture or spasm?)

#### MR enterography: Crohn's disease findings



## Wall thickening High SI wall / fat Deep ulcers Comb sign Enhancing nodes

Image courtesy of Jeff Fidler, MD





#### MR enterography: Crohn's disease findings



Wall thickening High SI wall / fat Deep ulcers Comb sign Enhancing nodes

Image courtesy of Jeff Fidler, MD






### MR enterography: Crohn's disease findings




Wall thickening High SI wall / fat Deep ulcers Comb sign Enhancing nodes

Image courtesy of Jeff Fidler, MD



Small bowel imaging in Crohn's disease: Prospective blinded 4-way study with consensus reference standard



CTE and CE were equally sensitive but CE was less specific than other 3 modalities


Solem et al, Gastroenterology 2005; 128: A74

## Indications for Endoscopy in IBD

- Obtain an accurate diagnosis
- Assess disease activity or possible extension
- Dilate strictures in fibro-stenotic disease
- Detect cancer precursors in long-standing colonic disease

Hommes Gastro 2004;126:1561-1573

## Endoscopic Features of IBD Ulcerative colitis



Edema

- Erythema/Loss of vascularity
  - **Friability**
- Erosions
  - Mucopurulent exudate
- Spontaneous bleeding
- Ulceration

## Endoscopic Features of IBD Crohn's Disease





- Patchy edema, erythema
   Discontinuous
- Apthous ulcerations
- Coalescing ulcerations
- Cobblestoning

## Differential Diagnosis of lleitis Conditions Mimicking Crohn's Disease

- Lymphoid hyperplasia
  - Adolescents, young adults
  - Could be clue to hypogammaglobulinemia

#### Infections


- M. tuberculosis
- Y. entercolitica (cold-chain hypothesis)
- E. histolytica
- Actinomyces (can cause fistulization)

#### Lymphoma

- NSAID induced injury
  - Ulcerations
  - Webs/strictures

- Vasculidities
  - Henoch-Schöenlein purpura (GI bleeding, RLQ pain)
  - Spondyloarthropathies
- Eosinophilic gastroenteritis
  - Predominantly eosinophilic infiltrate, sub-mucosal/serosal involvement
- Medications
  - Oral contraceptives
  - Ergot derivatives
  - Digoxin
    - precipitate small vessel thrombosis, ischemic ileitis
- CVID

## **Intestinal Tuberculosis**



http://admin.koreahospital.com

### Differential Diagnosis of Proctitis Conditions Mimicking Ulcerative Proctitis

#### Crohn's proctitis

- Associated with fistulas, fissures, skin tags, anal stricture

STDs

- HSV, gonorrhea, chlamydia, LGV, syphilis, whipworm

#### Rectal prolapse

Inflammation confined to distal 2-3cm of rectum

#### Solitary rectal ulcer syndrome

- Anterior location
- Fibrosis, muscular hypertrophy on biopsy


- ASLC
- Ischemic colitis
- Beçets syndrome
- Microscopic or collagenous colitis
- SCAD
- Diversion colitis



## Acute Self-Limited Colitis (ASLC) vs IBD

- Strongly suspected to be infectious in nature
   Whether or not an infectious agent is identified
- When enteric pathogen not identified, signs and symptoms distinguish poorly between ASLC and IBD
- Histopathology takes center stage in guiding accurate diagnosis


## **ASLC vs IBD**




#### Caveat

- Architectural distortion requires time to develop
- May not be identified in first 6-8 weeks of either form of IBD (potentially longer if inflammation is mild)

- ASLC
- Ischemic colitis
- Beçets syndrome
- Microscopic or collagenous colitis
- SCAD
- Diversion colitis



## **Ischemic Colitis**




http://admin.koreahospital.com


- ASLC
- Ischemic colitis
- Beçet's syndrome
- Microscopic or collagenous colitis
- SCAD
- Diversion colitis



- ASLC
- Ischemic colitis
- Beçet's syndrome
- Microscopic or collagenous colitis
- SCAD
- Diversion colitis



- ASLC
- Ischemic colitis
- Beçet's syndrome
- Microscopic or collagenous colitis
- SCAD
- Diversion colitis



## IBD Diagnosis-Summary and Pitfalls

#### Inflammation

- Gut really has limited options for expressing response to myriad of potential insults (one size fits all!)
- Minority of new occurrences of IBD associated with straightforward effort of establishing positive diagnosis
  - No gold standard test exists
  - Casual diagnosis of IBD has many ramifications
- Bottom line:
  - Diagnosing IBD correctly continues to be a challenge!

## **IBD** Treatment Principles





## Approach to Crohn's Disease Therapy

Determine Treatment Plan Based on Underlying Clinical Factors


- Disease behavior (inflammatory, fistulizing, stenotic/obstructing)
- Site/extent
- Presence of extra-intestinal manifestations
- Prior response to specific drugs
- Severity

## **Disease Behavior**

Inflammatory disease



 Mechanical obstruction (fibro-stenotic)



### Penetrating disease



# Provide Therapy Commensurate With Severity of Disease

### Clinical gestalt





### Measurement tools

- <u>Crohn's Disease Activity Index</u>
- Harvey Bradshaw Index
- Montreal Classification

## Crohn's Disease Activity Index

#### Variables

- Number of liquid or very soft stools
- Abdominal pain
- General well-being
- Number of listed complications
- -Use of antidiarrheal agents-Abdominal mass-Hematocrit
- -Change in standard body wt

- Measured over a 7-day period
- CDAI < 150: Remission</li>
- CDAI 151–220: Mild disease
- CDAI 220–450: Moderate to severe
- CDAI > 450: Severe disease

# <u>Harvey</u> <u>Bradshaw</u> <u>Index</u>

General well-being

0=very well, 1=below par, 2=poor, 3=very poor, 4=terrible

- Abdominal pain
   0=none, 1=mild, 2=moderate, 3=severe
- Number of liquid stools per day
- Abdominal mass

0=none, 1=dubious, 2=definite, 3=definite and tender

Complications

Arthralgia, uveitis, e. nodosum, p. gangrenosum, fistula, apthous ulcer, abscess (score 1 per item)

### Grading Activity

- <5 remission
- 5-7 mild disease
- 8-16 mod disease
- >16 severe disease

Response= > 3pt drop

## Determining Severity Clinical Gestalt

- Remission
  - Asymptomatic, off systemic steroids
  - No inflammatory sequelae
- Mild to moderate Crohn's disease
  - Ambulatory
  - Nontoxic
  - No abdominal tenderness, mass or obstruction
- Moderate to severe Crohn's disease
  - Unresponsive to mild/moderate therapy
  - Prominent fever, weight loss, anemia
  - Abdominal pain/tenderness, obstruction
- Severe Crohn's disease
  - Persistent symptoms on high dose prednisone
  - High fever
  - Rebound tenderness, abscess

# Therapy for Mild Disease

- Oral and topical 5-ASA compounds were firstline agents for patients with mild disease
  - No strong evidence to support therapeutic efficacy in Crohn's disease
- Budesonide: 9mg po daily
  - First choice for mild-moderate ileo-colonic CD
  - More effective than mesalamine
  - Fewer side effects than prednisone

## Therapy for Mod to Severe Disease

- Prednisone first-line therapy with Step-up theory of treatment selection
  - Proven efficacy
  - Rapid symptomatic relief
  - Dose as 40-60mg as single AM dose
- Consider early use of biologic therapy
- Immunomodulators
  - Azathioprine/6-mercaptopurine
  - Methotrexate

- Biologics
  - Remicade
  - Humira
  - Cimzia

## Therapy for Severe Crohn's Disease

- IV steroids
- Biologics
  - Remicade Tysabri
  - Humira
  - Cimzia
- Immunomodulators

   Methotrexate
   Azathioprine/6-mercaptopurine
- Surgery

## **Montreal Classification**

dx

L=location

B=behavior


A1	<16
A2	17-40
A3	>40
L1	TI
L2	colon
L3	ileocecal
L4	upper

B1 non-stric/penB2 stricturingB3 penetratingB4 peri-anal dz

- Risk factors
  - Age below 40
  - L1, L3
  - Penetrating or stricturing pheno
  - ASCA
  - Anti-OMPc
  - Anti-CBir1
  - Anti-I2
  - Steroid at dx

Beaugerie Gastro 2006

## **Azathioprine Metabolism**



### Approach to Ulcerative Colitis Therapy

## Selection of Treatment

- Treatment plan designed is based on
  - Severity
  - Extensive vs. distal
  - Presence of complications/extra-intestinal manifestations
  - Prior response to specific drugs
- Therapeutic decisions rarely based on severity of inflammation seen at endoscopy or histology

## **UC-Clinical Severity**

- Severity of disease can be determined by:
  - Truelove and Witt's criteria
    - mild
    - moderate
    - Severe
- Easy to remember:
  - 2 historical points
  - 2 physical exam points
  - 2 laboratory values

## UC Severity Truelove and Witt's Criteria

Variable	Mild	Severe	Fulm
Stools	<4	>6	Contin
Blood	Intermit	Freq	Contin
Temp	NI	>37.5	>37.5
Pulse	NI	>90	>90
Hgb	NI	<75% nl	Transf
ESR	<30mm	>30	>30

- All mild parameters = mild severity
- Fewer than all six severe = moderate


## **Ulcerative Colitis Activity Index**

1. Stool frequency	0-3: normal 1-3: 1-2 stools daily > normal 2-3: 3-4 stools 3-3: 4 stools	<ul> <li>Clinical response</li> <li>– Reduction from baseline <u>&gt;</u>3 pts</li> <li>+</li> </ul>
2. Rectal bleeding	0-3: None 1-3: Streaks of blood 2-3: Obvious blood 3-3: Mostly blood	<ul> <li>Reduction of bleeding</li> <li>2 1 pt</li> <li>or</li> </ul>
3.Mucosal appearance	0-3: Normal 1-3: Mild friability 2-3: Moderate friability 3-3: Exudation,	<ul> <li>Absolute score &lt; 1</li> <li>Clinical remission</li> </ul>
<ol> <li>Physician's rating of disease activity</li> </ol>	spontaneous bleeding 1-3: Normal 2-3: Mild 3-3: Moderate 4-3: Severe	<ul> <li>Score </li> <li>2pts</li> <li>+</li> <li>No individual score &gt;1</li> </ul>
Maximum score 3	13	

## Site of Delivery Based on 5-ASA Formulation

 Topical therapy's ability to reduce inflammation directly linked to ability to reach site of inflammation

20% pancolitis Oral



30-40% beyond sigmoid Enema

40-50% rectosigmoid Suppository

# **5-ASA Therapy**

- Best choice for mild to moderate disease
- Sulfasalazine
- Asacol (mesalamine)
- Lialda, (once daily mesalamine)
- Pentasa (mesalamine)
- Dipentum (olsalazine)
- Colazal (balsalazide)



### Rowasa (mesalamine)




Canasa (mesalamine)



# Principles of Topical Therapy

 Treats the rectal/colonic mucosa directly

 Best initial choice for active ulcerative proctitis/sigmoiditis



# **Topical Therapy Considerations**

- Topical mesalamine agents are superior to topical steroids or oral 5-ASA alone for left sided disease
- The combination of oral and topical aminosalicylates are more effective than either alone
- In patients refractory to oral aminosalicylates or topical steroids, mesalamine enemas or suppositories may still be effective (not dose dependent)
- Advantages of topical:
  - Quicker response time
  - Less frequent dosing
  - Fewer side effects than oral

Safdi AJG 1997 1867-71 Green Gastro 1998 15-22 Yang AJG 2001 S311-312

## Moderate to Severe UC

- Moderate will often respond to oral prednisone (40-60mg/d)
  - More severe may need admission
  - Outpatient management requires careful monitoring
- May begin steroid taper after patient clinically "well" (2-4 weeks)
  - Decrease prednisone by 5mg/wk until reaching 20mg
  - Below 20mg, taper by 2.5mg to 5mg per week
- Flare during taper should prompt increase to lowest level prior to flare
- Inability to complete taper should prompt consideration of immuno-modulators

Moderate to Severe UC Immunomodulators

- May require use of concomitant immunosuppression
- 6-mp/AZA have been shown to be helpful
- No role for methotrexate

### Moderate to Severe UC Anti-TNF Therapy

- If concomitant immuno-suppression ineffective, maximize therapy
- Consider Remicade for persistently active disease
  - 5mg/kg IV infusion 0, 2, 6 weeks, then q8 weeks
  - Same principles apply

### Severe Ulcerative Colitis General Treatment Guidelines

- Admit to hospital
   15% require at some point
- IV fluids/steroids
- GI consultation
- Surgical consultation
- Daily KUB/baseline ESR
- Consider clinical trial



## Severe Ulcerative Colitis Steroid Therapy

- Steroids may be administered in continuous or split dose
  - ACTH 120 units/24 hours as continuous infusion
    - If no steroids within previous 30 days
  - Hydrocortisone 100mg q 8 hours
  - Methylprednisolone 16-20mg q 8 hours\*
  - Prednisolone 30mg q 12 hours\*
- Continue for 7-10 days, as long as improvement continues
   If no improvement in 5-7 days, consider other therapy

### Severe Ulcerative Colitis 5-ASA Considerations

- No role for NPO (low residue diet)
- If already on 5-ASA products-STOP!!
- However, if not intolerant, concomitant administration of 5-ASA may improve short and long term response rates
  - 90% response rate when started early
  - 71% response without 5-ASA

### Severe Ulcerative Colitis Predicting Need for Second-Line Therapy

- Much of the morbidity/mortality associated with severe UC comes from delayed surgery
- Need to select patients who will benefit from additional therapy early in course of disease
- Two models predicted medical failure, early surgery:
  - Stool frequency >8/day, or 3-8/day with CRP>45mg/dL after 3 days steroid therapy: 85% require colectomy<sup>1</sup>
  - #BM + 0.14 x CRP (mg/L)>8.0 as optimal cut-off to predict medical failure<sup>2</sup>
  - 1. Travis et al. Gut 1996;38:905-10
  - 2. Lindgren et al. Eur J Gastroenterol Hepatol 1998;10:831-5

# **Fulminant Colitis**



- Medical emergency manifested by
  - high fever
  - abdominal tenderness, abdominal distension
  - hemorrhage
- May or may not have colonic distension
- Morbidity increased by delaying surgical therapy

# **UC-Indications for Surgery**

#### Immediate

- Toxicity and/or perforation
- Exsanguinating hemorrhage


### Urgent

- Unresponsive severe colitis
- Severe/acute complications of disease or therapy
  - Opportunistic infections
  - Steroid psychosis
  - Hemolytic anemia

Elective

- Suspected cancer
- Dysplasia
- Growth retardation
- Osteonecrosis or compression fracture
- Intractability

### Cancer Risk from UC/Crohn's Colitis




#### Extent AND duration of disease predictive factors

Eaden et al. Gut 2001;48:526-535

## Colorectal Cancer in Ulcerative Colitis Dysplasia

- Surveillance begins after 8 years
  - 33 biopsies required for 90% confidence of finding dysplasia<sup>1</sup>
- Low grade dysplasia associated with synchronous cancer 19%
   Debate over need for colectomy
- High grade dysplasia definite indication for colectomy

1. Rubin et al. Gastro 1992;103:1611-1620



# Night Call Scenarios

- Referring physician wants to transfer a 58 year old male with long-standing UC, admitted with a severe flare
  - Hospitalized for five days on IV steroids
    - Minimal relief
- What to do first?

# Night Call Scenarios

- ER calls with a 27 year old female with several year history of Crohn's disease
  - Presents with worsening fevers/chills, abdominal pain in RLQ, and diarrhea
    - Started on left-over Enterocort at home
    - No relief
- What to do?